Cervical cancer cells induce apoptosis of cytotoxic T lymphocytes
The goal of immunotherapy is to eliminate tumors by generating tumor-specific cytotoxic T lymphocytes (CTLs) in patients or by adoptively transferring ex vivo-activated CTLs into patients. Clinical trials have shown that tumor-specific CTLs often disappear before tumors are completely eliminated. In...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
January 2000
|
| In: |
Journal of immunotherapy
Year: 2000, Volume: 23, Issue: 1, Pages: 67-74 |
| ISSN: | 1537-4513 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://journals.lww.com/immunotherapy-journal/fulltext/2000/01000/cervical_cancer_cells_induce_apoptosis_of.9.aspx
|
| Author Notes: | Diana N. Contreras, Peter H. Krammer, Ronald K. Potkul, Ping Bu, Juan L. Rossi, Andreas M. Kaufmann, Lutz Gissmann, Liang Qiao |
| Summary: | The goal of immunotherapy is to eliminate tumors by generating tumor-specific cytotoxic T lymphocytes (CTLs) in patients or by adoptively transferring ex vivo-activated CTLs into patients. Clinical trials have shown that tumor-specific CTLs often disappear before tumors are completely eliminated. In this study, the authors show that CTLs specific for cervical tumor cells undergo apoptosis after they are co-cultured with cervical tumor cells. The established cervical tumor cell lines and cervical cancer tissues express CD95 (Fas/Apo-1) ligand. The tumor cell-induced T-cell apoptosis can be blocked by an inhibitory anti-CD95 (APO-1/Fas) antibody, indicating that tumor cells induce apoptosis of CTLs through CD95-CD95 ligand interaction. Addition of interleukin-2 (IL-2) and IL-7 into the culture rescues the CTL from tumor cell-induced apoptosis. The rescued T cells retain their full antitumor cytotoxicity. These data suggest that human cervical tumor cells might actively downregulate a cellular immune response by inducing apoptosis of specific T cells during immunotherapy. Local use of IL-2 and IL-7 as adjuvants may promote survival of the CTL and, thus, enhance the efficacy of immunotherapy. |
|---|---|
| Item Description: | Gesehen am 26.04.2021 |
| Physical Description: | Online Resource |
| ISSN: | 1537-4513 |